Status:

Do Not Prescribe (DNP), Red

Decision Date:

June 2019

Comments

RED:

•NICE TA578: Locally advanced, unresectable non-small cell lung cancer after platinum-based chemoradiation.  (Decision date - June 2019).

•NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. (NHSE commissioned).  (Decision date - July 2022).

•NICE TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer as per  NHSE commissioned (Decision date - February 2024)

•NICE TA1030: Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (decision date Feb 2025)

NICE TA1041: Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (decision date March 25)
DNP: NICE TA662: in combination for untreated extensive-stage small cell lung cancer.  (Terminated appraisal).  (Decision date - December 2020).

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again